Isoguanosine-Induced ER Stress via AMPK Enhances Chemosensitivity in OSCC

J Yao1, S Song1, T Liu1

  • 1State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Research Unit of Oral Carcinogenesis and Management & Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.

PubMed

Insights

Isoguanosine (isoG) enhances oral cancer treatment by activating AMPK, inducing ER stress, and improving chemotherapy sensitivity. A novel isoG-based platform combined with 5-FU shows significant tumor inhibition in preclinical models.

Area of Science:

  • Biochemistry
  • Oncology
  • Materials Science

Background:

  • Oral squamous cell carcinoma (OSCC) presents limited treatment options.
  • Isoguanosine (isoG) shows anti-OSCC potential but its mechanism is unknown.
  • Developing novel therapeutic strategies for OSCC is crucial.

Purpose of the Study:

  • To elucidate the antitumor mechanism of isoguanosine (isoG) in OSCC.
  • To investigate isoG's role in modulating chemosensitivity.
  • To develop and evaluate a novel isoG-based therapeutic platform for OSCC.

Main Methods:

  • Investigated isoG's metabolite, isoguanosine 5'-monophosphate (isoGMP), and its effect on endoplasmic reticulum (ER) stress and adenosine monophosphate-activated protein kinase (AMPK) activation.
  • Assessed the combined effect of isoG and 5-fluorouracil (5-FU) on OSCC cells.
  • Developed an isoG-phenylenediboronic acid-isoG (isoGPBisoG) structure and evaluated its efficacy in combination with 5-FU in OSCC xenograft models.

Main Results:

  • IsoG's antiproliferative effect is mediated by isoGMP, inducing ER stress and cell death via AMPK activation.
  • AMPK activation by isoG enhances OSCC cell sensitivity to 5-FU, leading to synergistic anticancer effects.
  • The isoGPBisoG and 5-FU combination demonstrated significant tumor inhibition (71.0% and 56.6%) in OSCC xenograft models.

Conclusions:

  • Isoguanosine (isoG) is a potent enhancer of chemotherapeutic efficacy in OSCC through AMPK activation.
  • The isoGPBisoG and 5-FU combination represents a promising synergistic therapy platform for OSCC.
  • This novel approach offers a new direction for developing more effective OSCC treatments.